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Abstract Although contributing to inflammatory respon-
ses and to the development of certain autoimmune
pathologies, type I interferons (IFNs) are used for the
treatment of viral, malignant, and even inflammatory
diseases. Interleukin-1 (IL-1) is a strongly pyrogenic
cytokine and its importance in the development of several
inflammatory diseases is clearly established. While the
therapeutic use of IL-1 blocking agents is particularly
successful in the treatment of innate-driven inflammatory
disorders, IFN treatment has mostly been appreciated in the
management of multiple sclerosis. Interestingly, type I
IFNs exert multifaceted immunomodulatory effects,
including the reduction of IL-1 production, an outcome that
could contribute to its efficacy in the treatment of inflam-
matory diseases. In this review, we summarize the current
knowledge on IL-1 and IFN effects in different inflam-
matory disorders, the influence of IFNs on IL-1 production,
and discuss possible therapeutic avenues based on these
observations.
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Introduction
In this review, we focus on IFNs and give a background on
their biological functions, emphasizing their anti-inflam-
matory effects in infections as well as in their therapeutic
use. We summarize the knowledge on the complex mech-
anisms leading to IL-1 production and on its role in the
development of various inflammatory disorders. Increasing
evidence underlines the ability of IFNs to affect IL-1
production, and these findings potentially impact the man-
agement of infectious and inflammatory disorders. Here, we
concentrate on the interplay between these two cytokines
and possible clinical implications.
Inflammation
An inflammatory reaction is initiated whenever the normal
equilibrium of the tissue is altered. Inflammation is
required to remove the agent that caused the damage and to
restore normality [1]. This is mainly achieved by cells of
the immune system and by the action of different factors
found in blood plasma and in extracellular fluids.
The classical signs of inflammation were already recog-
nized by Celsus at the time of Ancient Greece and are
described as the characteristic redness (rubor), swelling
(tumor), increased temperature (calor), and pain (dolor) in
the inflamed area. In fact, the primary goal of inflammatory
responses is to increase blood supply and vessel permeability
within the damaged tissues, thus promoting plasma protein
and immune cell exudation. This facilitates tissue repair
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processes and minimizes the risk of infection. Indeed, when
tightly controlled and actively terminated, inflammation
represents a protective response, which coordinates tissue
healing as well as immune cell activation and migration.
However, if not properly held in check, overriding
inflammatory reactions can be detrimental to the tissue and
lead to important collateral damage. This is the reason why
a fifth hallmark, the ‘Functio laesa’ (i.e., loss of fuction),
attributed to the Roman physician Galen, has been added to
the four cardinal signs of inflammation. Importantly,
chronic inflammation-driven diseases are a major health
issue, particularly in developed countries, and selected
examples are discussed later.
Mechanisms inducing innate-driven inflammation
Classical triggers of inflammatory responses are tissue
damage and infectious agents. Innate immune cells, being
strategically located at the site of injury, propagate the first
alarm signal to recruit immune cells and to coordinate local
tissue repair. Cells of the innate immune system have the
ability to immediately respond to pathogen- and danger-
associated molecular patterns (PAMPs and DAMPs,
respectively) through dedicated germ-line encoded recep-
tors, the so-called pattern recognition receptors (PRRs).
Whilst PRRs lack the specificity and plasticity of their
more sophisticated adaptive counterparts (T and B cell
receptors), they mediate rapid and robust innate immune
responses. Upon engagement, these receptors activate
multiple signaling pathways that orchestrate the overall
immune response, including the adaptive system.
To date, several classes of innate receptors have been
defined [2–5]. We mainly focus on Toll-, Retinoic acid-
inducible gene (RIG)-, and Nucleotide-binding oligomeri-
zation domain (NOD)-like receptors (TLRs, RLRs, and
NLRs, respectively), that are particularly relevant to the
induction of IFNs and IL-1.
Interleukin-1
The IL-1 family consists of 11 related ligands. Although a
few members have been extensively investigated, others
are neglected and await more in depth analysis. The most
studied family members are the functionally related IL-1a
and IL-1b (IL-1a and IL-1b are referred here as to ‘IL-1’),
IL-1 receptor antagonist (IL-1Ra), and the IFN- c-inducing
cytokine IL-18.
Biological effects of IL-1
IL-1a and IL-1b, which share 26 % sequence homology,
exert pleiotropic activities. Interleukin-1 represents an
important mediator linking the immune, the endocrine, and
the central nervous system, therefore affecting several
physiological functions [6–8]. Yet, IL-1 is best known for
its ability to induce fever and for this reason was formerly
called ‘endogenous pyrogen’ [7].
In fact, this cytokine is instrumental in inducing
inflammation through activation of the nuclear factor-jB
(NF-jB) pathway. Both IL-1a and IL-1b signal via a
common IL-1 receptor (IL-1R) that is formed by the
association of IL-1RI and the IL-1R accessory protein [9].
Interleukin-1R represents the prototypical NF-jB activat-
ing Toll/Interleukin-1 receptor (TIR) domain-containing
receptor and engages the NF-jB signaling cascade through
the adapter myeloid differentiation factor 88 (MyD88) and
the IL-1 receptor-associated kinases (IRAKs) [10–13].
Interleukin-1 induces a variety of inflammatory media-
tors, such as the neutrophil chemoattractant CXCL1, and
promotes growth/activation of hematopoietic cells by
inducing cytokines such as IL-6 or the granulocyte–mac-
rophage colony-stimulating factor [14–18]. In the early
1990s, the properties of IL-1 in helping hematopoietic
reconstitution in bone marrow-transplanted patients have
been evaluated, as summarized by Dinarello [15]. Unfor-
tunately, side effects such as inflammation and hypotension
were too severe to pursue the use of IL-1 as a therapeutic
agent. However, IL-1a and IL-1b were efficacious in
reducing thrombocytopenia and leucopenia, in particular
with regard to neutrophil counts. Another name that has
been assigned to IL-1 in the past was ‘lymphocyte acti-
vating factor’, due to its ability to promote lymphocyte
proliferation [19]. The interest in this field was recently
revitalized, as it was shown that IL-1 plays a crucial role in
promoting CD4? T cell polarization towards a T helper
type 17-phenotype (Th17) [20, 21]. These are helper T
cells secreting IL-17 (also known as IL-17A), which are
mainly involved in autoimmune diseases and antifungal
responses. Furthermore, another report demonstrated that
IL-1 had the property of opposing the function of regula-
tory T cells, thus restoring the response of conventional T
lymphocytes [22]. Altogether, these studies highlight the
contribution of IL-1 in both innate and adaptive immune
responses.
Such important inflammatory effects require tight reg-
ulation of IL-1 production and signaling. As discussed in
more detail in the next paragraph, the generation of bio-
active IL-1 is a complex process controlled at multiple
levels. In addition, IL-1 signaling is held in check by its
antagonist IL-1Ra, which is a protein sharing 26 %
homology with IL-1b and 18 % with IL-1a. This naturally
occurring inhibitor strongly binds IL-1RI without activat-
ing it and defects in its production lead to early onset life-
threatening inflammatory diseases [23–26]. The crucial
role of IL-1 in the development of inflammatory
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pathologies has been increasingly studied and recognized
over the past few years (reviewed in [14, 27]).
Multilevel control of bioactive IL-1 production
Interleukin-1 is mainly, but not exclusively, produced by
myeloid cells. Given its strong and complex effects, its
production is regulated at the transcriptional, translational,
and posttranslational levels (Fig. 1). In fact, IL-1a and the
inactive precursor of IL-1b (called pro-IL-1b) are virtually
undetectable in blood cells under normal conditions, and
their induction needs the presence of stress signals [28]. In
well-studied myeloid immune cells, IL-1 transcription
relies on NF-jB activating signals, such as tumor necrosis
factor (TNF) or lipopolysaccharide (LPS) [29]. This
‘priming’ step is thus essential to raise intracellular levels
of IL-1a and pro-IL-1b, along with enhancing the compe-
tence of the cell to proteolytically activate and secrete
IL-1b [30–32].
Interleukin-1b mRNA is short-lived, giving rise to a
tightly controlled burst of protein [33, 34]. Moreover, dis-
sociation between the transcriptional and the translational
regulation of this gene has been observed. Whereas, the
stimulation of peripheral blood mononuclear cells with LPS
increased both IL-1b mRNA and protein, the adhesion of
these cells to plastic surface or exposure to the complement
system factor C5a augmented transcript abundance, lead-
ing, however, to abortive translation [35–37]. Under such
conditions, IL-1b transcripts assemble into large polyribo-
somes without giving rise to substantial protein levels.
Whereas IL-1a is biologically active as it is synthesized,
IL-1b is produced as a precursor protein, which is per se
inactive; proteolytic processing is required to convert the
precursor protein into its active counterpart [38]. Several
years ago, caspase-1 was identified as the crucial protease
responsible for pro-IL-1b maturation and was called
‘IL-1b-converting enzyme’ thereafter [39–41]. However,
the molecular mechanism leading to caspase-1 activation
has only been described recently [42]. Its activation is
accomplished upon formation of multiprotein complexes,
called inflammasomes, which are able to bring caspases in
close proximity to promote their autoactivation (discussed
in more detail in the next section). A second member of the
IL-1 family, IL-18, also requires caspase-1-dependent pro-
cessing in order to be bioactive. Notably, although IL-1a
activity is independent of its cleavage, its secretion has
often been observed in association with inflammasome
function [17, 40, 43, 44].
NLRs and inflammasomes
NOD-like receptors are mainly recognized for their
important role in the activation of inflammatory cascades in
response to different PAMPs and DAMPs [4, 45, 46]. This
family of proteins is characterized by a tripartite structure.
The N-terminus, which is also called ‘effector domain’, is
responsible for the recruitment of downstream executioner
proteins and consists in most cases of a caspase recruitment
or a pyrin domain (CARD or PYD, respectively). In
addition, NLRs have a central NOD domain and a C-ter-
minal tail of leucine-rich repeats (LRRs) [45].
Amongst the best-characterized NLRs, we find NLRP3
(previously called NALP3 or cryopyrin), NLRP1, and NLR
family CARD-containing (NLRC) 4 (previously known as
IPAF). These three family members share the ability to
form inflammasome platforms, which have been studied in
Fig. 1 The production of
bioactive IL-1. Pattern
recognition receptor
engagement enhances NLRP3
expression and induces IL-1a
and pro-IL-1b. Upon sensing
specific inflammasome-
activating stimuli, NLRP3
assembles into and recruits
ASC and procaspase-1 to the
inflammasome complex. This
multi-protein platform leads to
the activation of caspase-1,
which proteolytically converts
pro-IL-1b into bioactive IL-1b.
In contrast, pro-IL-1a does not
require cleavage for its activity.
The release of both cytokines
triggers NF-jB signaling by
binding to IL-1R
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detail by means of biochemical and genetic approaches.
Upon activation, NLRP3 recruits caspase-1 into the inflam-
masome complex via the adaptor protein ASC (apoptosis-
associated speck-like protein containing a CARD), which is
a bipartite protein formed by a CARD and a PYD domain.
ASC joins the oligomerized NLRP3 proteins through PYD–
PYD interactions, while its CARD is available for homotypic
interaction with the N-terminal CARD of caspase-1. In
contrast to NLRP3, NLRC4 bears an N-terminal CARD,
whereby caspase-1 can be directly recruited into the complex
via homotypic CARD–CARD interactions. Nonetheless, the
presence of ASC has been shown to favor NLRC4 inflam-
masome activity [47].
NOD-like receptor family CARD-containing protein 4
(NLRC4) with the assistance of neuronal apoptosis inhib-
itory proteins (NAIPs), another subgroup of NLR proteins,
senses distinct Gram-negative bacteria. In particular, the
role of NLRC4 in the response to flagellin has been
investigated (Table 1) [46, 48–50]. The NLRP1 inflam-
masome was historically the first to be described, and the
NLRP1b murine paralog activates caspase-1 upon expo-
sure to lethal toxin of Bacillus anthracis [42, 51]
(Table 1). To date, the activation of the NLRP3 inflam-
masome remains the most enigmatic. Indeed, this
cytoplasmic protein leads to inflammasome assembly upon
an ever-growing number of triggers, which belong to
completely different chemical and physical categories (as
summarized in Table 1, and reviewed in several articles
[46, 52–54]). For example, NLRP3 can respond to stimu-
lation with extracellular ATP, with pathogens and PAMPs,
or to particulate stimuli such as monosodium urate crystals
and asbestos fibers. How such diverse stimuli activate
inflammasome formation specifically through NLRP3 is
subject of intense research, and proposed models suggest
the activation or induction of a common secondary effector
molecule [31, 53]. Recent reports on Nlrp6-knockout ani-
mals and on human NLRP12 variants support the idea that
these NLRs may be similarly involved in inflammasome
complex formation [55–57].
Finally, also absent in melanoma 2 (AIM2), not
belonging to the NLR family, has been shown to form an
inflammasome. This protein of the IFI200 family of pro-
teins recruits and activates caspase-1 upon binding to
double-stranded (ds) DNA in the cytoplasm (Table 1) [58].
Interferons
IFNs were discovered over half a century ago as endoge-
nous antiviral effector molecules. These cytokines were
named after their ability to ‘interfere’ with viral replication
in the host cell. However, IFNs mediate a variety of
biological functions not limited to the defense against viral
infections, extending to antitumor and immunomodulatory
effects [59]. According to their amino acid sequence,
chromosomal location, and receptor specificity, IFNs are
further subdivided into three groups, which we describe
below.
IFN subtypes
Introduction to type I IFNs
Interferon-a and -b are the most studied and therefore best-
characterized members of this class. Interferon-b is enco-
ded by a single gene in human and mouse, and more than
20 different genes code for IFN-a, thereof 13 give rise to
a functional protein in humans and 14 in mice. Whereas
IFN-a and -b regulate a widely overlapping set of genes,
these two cytokines are described as slightly differing in
their downstream effects and in their expression pattern,
which varies depending on the stimulation, on the cell type,
and among individuals [60–63].
Table 1 List of inflammasome activators
Origin Trigger Sensor protein
Sterile activators
Endogenous signals ATP NLRP3
MSU crystals NLRP3
CPPD crystals NLRP3
BCP crystals NLRP3
Cholesterol crystals NLRP3
Glucose/hyperglycemia NLRP3
Amyloid-b NLRP3
Hyaluronan NLRP3
Environmental-
derived
Skin irritants NLRP3
UV NLRP3
Alum NLRP3
Asbestos NLRP3
Silica NLRP3
Microorganisms—PAMPs
Viral RNA NLRP3, AIM2
DNA AIM2
Bacterial RNA NLRP3
DNA AIM2
Flagellin NLRC4
Type III secretion system NLRC4, NLRP3
Cell wall components NLRP1, NLRP3
Pore-forming toxins NLRP1, NLRP3
Fungal Hyphae, b-glucan NLRP3
Protozoan-derived Haemozoin NLRP3
Helminth-derived (unknown) NLRP3
3398 K. Ludigs et al.
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Other type I subtypes are IFN-e, -j, -x, -d, and -s.
Interferon-d and -s are only found in pigs and cattle,
respectively, and have no human homologs. IFN-e, -j, and
-x exist in humans but are less well described and show
restricted tissue distribution [60]. Induction, signaling, and
downstream effects of IFN-a and -b are discussed in detail
in the following sections.
Type II IFN
The type II IFN subtype is constituted by a single gene
product, IFN-c. It is structurally different from type I IFNs,
but was classified in the IFN family due to its antiviral
effects [64, 65]. Interferon-c binds to the nearly ubiqui-
tously expressed IFN-c receptor (IFNGR), and signals
through Janus kinase 1 (JAK1) and JAK2 to phosphorylate
signal transducer and activator of transcription 1 (STAT1),
thereby allowing STAT1 homodimer formation and
nuclear translocation.
Interferon-c is involved in the modulation of immune
and inflammatory responses and is predominantly produced
by NK, NKT, and activated T cells. In the latter, IFN-c
leads to the upregulation of the transcription factor T-bet,
which is crucial for controlling commitment to the Th1
phenotype [66]. T helper 1 cells are characterized by IFN-c
production and suited to fight viral infections. In fact, T-bet
upregulation drives IFN-c expression and creates a positive
feedback loop, which forces undifferentiated CD4? cells to
Th1 polarization. Furthermore, IFN-c favors Th1 commit-
ment indirectly by suppressing polarization to Th17 and
Th2 [66, 67], the latter being a subtype of helper T cells
mainly involved in allergic and helminth responses, dis-
tinguished by the production of IL-4 and IL-13.
Interferon-c also exerts immunomodulatory effects on
innate immune cells, primarily by increasing lysosomal
enzymatic activity and bactericidal oxidative burst [68].
Moreover, type II IFN directly enhances antigen presen-
tation by promoting antigen processing and by inducing the
expression of major histocompatibility complex (MHC)
molecules [65, 68].
Type III IFNs
The third class of IFNs is composed of IFN-k1, -k2, and
-k3, or IL-28A, IL-28B, and IL-29, respectively. They are
produced by most cell types, but particularly by plasma-
cytoid dendritic cells (DCs) in response to viral or bacterial
infection [69, 70]. k-Interferons form a separate group as
they signal through a distinct receptor complex, consisting
of IL-10R2 and IL-28R, which is expressed on a limited
number of cells like hepatocytes and epithelial cells [70,
71]. However, type III IFNs activate similar signaling
pathways and partly induce the same genes as type I IFNs,
resulting in a potent antiviral response [72, 73].
Type I IFN production
Interferon-a and -b can be produced by almost all cell types
upon stimulation of PRRs. Constitutive expression of low
type I IFN levels is maintained by macrophages, skin DCs,
and thymic epithelial cells and is also found in organs like
liver, spleen, and kidney [74–77]. Basal IFN signaling is
important to keep immune cells in a ‘primed’ state to
rapidly and effectively mount an antiviral immune
response [78].
Cytoplasmic receptors
Most cell types can induce type I IFN in response to the
activation of cytoplasmic RLRs (Fig. 2a), which are nearly
ubiquitously expressed [5]. Importantly, the strategic
intracellular location of these PRRs allows infected cells to
activate the antiviral response. Retinoic acid-inducible
gene-like receptors detect microbial ribonucleic acids,
which can derive from the genome of RNA viruses or from
replication intermediates of DNA viruses [79]. These
receptors therefore enable infected cells to locally produce
antiviral type I IFNs, which are essential in opposing a
number of viral infections [5, 80].
Retinoic acid-inducible gene-like receptors include the
two DExD/H-box helicases RIG-I and melanoma differ-
entiation-associated gene 5 (MDA5), which are engaged by
distinct ribonucleic acid species. Retinoic acid-inducible
gene-I detects 50 triphosphate single-stranded (ss) RNA
with pairing at the 50 end and rather short dsRNA, while
MDA5 is activated by long dsRNA [5].
Retinoic acid-inducible gene-I and MDA5 have a
common downstream adaptor, called mitochondrial anti-
viral signaling protein (MAVS) (Fig. 2a) [5]. Engagement
of MAVS is followed by signaling through TBK1 [TNF
receptor-associated factor (TRAF) family member-asso-
ciated NF-jB activator (TANK)-binding kinase 1] and the
IjB kinase e (IKKe), leading to the activation of the
transcription factors interferon-regulatory factor (IRF) 3,
IRF7, and NF-jB [5, 80, 81]. Phosphorylation of IRFs
allows their homo- or heterodimerization and promotes
their subsequent localization to the nucleus, where they
cooperate with NF-jB to stimulate the transcription of
type I IFN genes [82] (Fig. 2a). In most cells, IRF3 is the
only constitutively expressed IRF. The phosphorylation of
IRF3 results in the induction of IFN-b and low levels of
IFN-a4 [83]. IRF3-triggered type I IFN increases IRF7
levels, which then lead to the proficient expression of
IFN-a [84].
IFN regulation of IL-1 production 3399
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In addition to RNA, sensing of cytoplasmic DNA also
results in the induction of type I IFNs. Proposed DNA
receptors are the DNA-dependent activator of IRFs (DAI)
and the DNA-dependent RNA polymerase III [85]. The
latter transcribes dsDNA into a 50triphosphate dsRNA,
which is recognized by RIG-I. More recently, the AIM2-
like molecule IFI16 and other members of the DExD/
H-box helicase superfamily have been described as contrib-
uting to the sensing of cytoplasmic DNA [85]. Downstream of
these DNA sensors, the ER-localized stimulator of IFN
genes (STING) serves as a recruitment platform to activate
TBK1, which in turn phosphorylates IRF3/7, resulting in the
induction of type I IFNs [86].
Transmembrane receptors
Interferon production in immune cells can also be induced
by the activation of transmembrane TLRs (Fig. 2a). The
expression of TLRs is mainly restricted to tissues and cell
types involved in innate immunity, such as macrophages
and dendritic cells (DCs) [87, 88]. Toll-like receptors
recognize structurally conserved molecules derived from
microbes through their LRRs. While TLR3 senses viral
dsRNA, TLR7 and TLR8 recognize ssRNA. Toll-like
receptor 9 detects unmethylated CpG-containing oligonu-
cleotides, typical of microbial DNA, and TLR4 responds to
LPS, a cell wall component of Gram-negative bacteria
(a detailed description of TLR ligands can be found in
[2, 88]). These receptors are localized either in endosomal
compartments (TLR3, 7, 8, 9,) or at the cell surface (TLR3,
4). They are thus devoted to the recognition of PAMPs
upon phagocytosis or after lysis and release of material by
a pathogen or an infected cell.
All TLRs except TLR3 trigger signaling cascades via
MyD88. TLR3 associates instead with TRIF (TIR-domain-
containing adapter inducing IFN-b), whereas TLR4 uses
both TRIF and MyD88 [2]. Similarly to RLRs, engagement
of the TRIF-dependent pathway downstream of TLR3 and
TLR4 activates TBK1 and IKKe, leading to the phos-
phorylation of IRFs. Type I IFN induction by endoplasmic
TLR7, TLR8, and TLR9 is instead mediated by an MyD88-
dependent complex including IRAK1 and IKKa, which
phosphorylate and thereby activate IRF7 [89].
The main producers of type I (and III) IFNs are plas-
macytoid DCs, a population of circulating DCs [90]. These
‘specialized IFN-producing cells’ are characterized by
rapid and potent IFN production, which is dependent on the
activation of TLR7 and TLR9. Indeed, high constitutive
expression of these TLRs and of the downstream signaling
molecule IRF7 leads to a very efficient coupling of ligand
detection to cytokine production [91]. Thus, plasmacytoid
DC are particularly important to produce systemic type I
IFN, which is crucial to alert the entire organism.
Type I IFN signaling
Interferon-a and -b share a common receptor, the IFN-a
receptor (IFNAR), composed of a IFNAR1 and a IFNAR2
subunit (Fig. 2b) [64]. These cytokines can signal in vir-
tually every cell, as the receptor is ubiquitously expressed.
Ligand-induced receptor dimerization leads to the auto-
and trans-phosphorylation of receptor-associated tyrosine
Fig. 2 Induction and effects of type I IFNs. a The best characterized
mechanisms leading to type I IFN induction are initiated by
cytoplasmic RLRs and transmembrane TLRs. Signaling pathways
activated by these receptors converge in the phosphorylation of IRFs,
which translocate into the nucleus and activate the transcription of
type I IFN genes. b Type I IFNs signal through a dimeric receptor and
activate JAK1 and TYK2. In turn, these kinases phosphorylate
STAT1 and STAT2, enabling recruitment of IRF9 to the so-called
ISGF3 complex. This trimeric complex binds to ISREs, thereby
modulating the expression of ISGs exerting antiviral, immunomod-
ulatory, proapoptotic, and anti-inflammatory functions
3400 K. Ludigs et al.
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kinases JAK1 (on IFNAR2) and TYK2 (on IFNAR1).
Janus kinase 1 and Tyrosine kinase 2 then phosphorylate
the intracellular domain of IFNAR, which creates docking
sites for STAT1 and STAT2. These two transcription fac-
tors heterodimerize, bind to IRF9, and translocate to the
nucleus (Fig. 2b) [92]. This heterotrimer [also known as
IFN-stimulated gene factor 3 (ISGF3)] binds to genomic
IFN-stimulated response elements (ISREs), thereby mod-
ulating the expression of numerous IFN-stimulated genes
(ISGs). Interferon-stimulated genes encode factors
involved in the antiviral and anti-inflammatory response, in
immunomodulation, and factors endowed with pro-apop-
totic and anti-proliferative activities (Fig. 2b) [61, 93].
Importantly, ISGs also code for proteins that augment
IFN signaling by a positive feedback loop. Firstly, the
expression of the nucleic acid receptors RIG-I, MDA5, DAI,
and of TLRs is positively regulated by type I IFNs [94].
Secondly, ISGs encode signaling molecules involved in the
IFN pathway, such as IRF7 and STAT1. Furthermore, all
genes encoding type I IFNs contain ISREs in their promot-
ers, resulting in a self-amplifying loop (Fig. 2b) [61, 95].
Although ISGF3 mediates the most studied and proba-
bly the major effects of type I IFNs, other STAT family
members can participate in type I IFN signaling. Homo-
and heterodimers of STAT1, STAT3, STAT4, STAT5, and
STAT6 can play a role downstream of IFNAR [64].
Moreover, type I IFNs have also been described to activate
other signaling pathways such as mitogen-activated protein
and phosphatidylinositol-3 kinases [96].
Effects of type I IFNs
The following sections focus on the antiviral, pro-apoptotic,
immunomodulatory, and in particular anti-inflammatory
activities of type I IFNs. Emerging evidence indicates that
IFN-b and the different a-subtypes can vary in these effects
[97, 98]. This may be explained by the different binding
properties of IFN-a and -b to IFNAR, influencing down-
stream signaling [97, 99]. Therefore, in some cases, we
discuss the diverging activities of b- and a-IFNs.
Antiviral effects
Type I IFNs were initially discovered and best described as
effector molecules in the protection against viral infections.
They have the ability to induce an antiviral state in infec-
ted, but also in neighboring cells by autocrine and
paracrine effects. Interferon-stimulated genes code for
proteins that target virtually all steps of the virus life cycle,
including entry, transcription, and translation, and lead to
viral RNA degradation.
A prime example of an antiviral effector molecule is the
dsRNA-dependent protein kinase R (PKR). Upon PKR
activation, the a-subunit of the eukaryotic translational
initiation factor 2 (eIF2a) is phosphorylated, which results
in the inhibition of cellular as well as viral mRNA trans-
lation [100]. Further, the translational suppression triggered
by PKR is also linked to IFN-induced cell-cycle arrest and
apoptosis [101–103]. Not being central to this work, we
refer the reader to excellent reviews in which the antiviral
effects of IFNs have been summarized [103, 104].
Immunomodulation
In addition to their direct antiviral effects, type I IFNs play a
major role in modulating innate and adaptive immunity.
Notably, they are involved in regulating homeostasis, sur-
vival, differentiation, and trafficking of immune cells [105].
To start with, these cytokines play an important role in
promoting the maturation of DCs, which are required for
efficient activation of T cells [106, 107]. In fact, type I IFNs
enhance antigen presentation, in particular by increasing the
expression of costimulatory and MHC class I molecules
[108, 109].
Type I IFN signaling has also been described to directly
act on T cells as it can induce the production of IFN-c
through activation of STAT4, thereby favoring induction
and maintenance of Th1 cells [110, 111]. Some reports
claim that type I IFNs are, however, not sufficient to pro-
mote Th1 differentiation as the phosphorylation of STAT4
occurs only transiently. In both human and mouse cells,
IL-12 has been proven to be necessary to induce adequate
levels of the transcription factor T-bet, thereby leading to
Th1 polarization [112, 113]. Nevertheless, IL-18 has been
described to act with type I IFNs to activate STAT4 in the
absence of IL-12 [114]. Type I IFNs are likely to also
indirectly contribute to Th1 differentiation. They do so by
inhibiting the ability of IL-4 to promote Th2 commitment
and to antagonize Th1 development [115, 116]. Similarly,
IFNs are involved in the negative regulation of Th17
development [117, 118]. Interferon-b has been described to
induce the expression of IL-27 via STAT1. Interleukin-27
in turn downregulates IL-17 and IL-23, the latter being
required for Th17 maintenance [119, 120].
In addition, type I IFNs seem to play a role in the sur-
vival of activated CD4? T cells. Despite the fact that IFNs
have been described as promoting cell growth arrest and
even apoptosis [121, 122], these cytokines seem to protect
T cells from apoptosis induction upon antigen encounter
and enhance the development of central memory-like
CD4? T cells [123, 124].
Type I IFNs are also able to induce efficient CD8? T
cell responses by promoting DC cross-presentation. This
process defines the ability of DCs to take up extracellular
antigens by endocytosis and present them via MHCI to
CD8? T cells [107]. Furthermore, the augmented MHCI
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levels increase the presentation of peptides to cytotoxic T
cells, thus leading to augmented recognition and killing of
infected cells. Type I IFNs also support CD8? T cell
responses by directly enhancing effector functions,
including IFN-c secretion and expression of perforin and
granzymes [125, 126]. An increase in the cytotoxic
capacity has also been observed for NK cells and macro-
phages [127], highlighting the immunomodulatory effects
of type I IFNs on these cell types as well. Notably, high
levels of IL-15 induced in DCs by type I IFNs during their
maturation lead to a selective stimulation and maintenance
of memory CD8? T cells [128, 129] and also favor NK cell
development and differentiation [130]. Besides modulating
T cell activation, type I IFNs also influence their migration
by the induction of chemoattractants, such as CXCL10 and
CXCL11 [131].
Direct and indirect effects of type I IFNs have also been
described for B cells. These cytokines can enhance anti-
body production by promoting isotype switch and by
inducing two TNF-family members important for B cell
survival and homeostasis, namely B cell-activating factor
(BAFF) and a proliferation-inducing ligand (APRIL) [132,
133]. In addition, treatment with type I IFNs has been
shown to protect B cells from apoptosis [134]. Therefore,
these cytokines seem to also contribute to the induction and
maintenance of a potent humoral immune response [132].
Altogether, type I IFNs play a crucial role in the regulation
of immune responses, by directly affecting functions of
lymphocytes and antigen presentation.
Apoptosis
In contrast to the aforementioned anti-apoptotic effects in
lymphocytes, type I IFNs have often been described to
have anti-proliferative activity and to sensitize infected or
transformed cells to apoptosis [122, 135]. These anti-pro-
liferative effects were correlated with an inhibition of the
NF-jB pathway [136], which, however, requires higher
doses of IFNs than the induction of an antiviral state.
Although type I IFNs are insufficient per se to induce
death in most cell types, they can sensitize cells to apop-
tosis via upregulation of caspases, pro-apoptotic, and tumor
suppressor genes [137–139]. Furthermore, the induction of
multiple antiviral proteins affects viral replication by sig-
nificantly interfering with essential cellular processes. As
an example, several studies have assigned a pro-apoptotic
role to the IFN-inducible PKR, which is in part linked to
the translation blockade induced by this kinase [140–142].
Type I IFNs have also been shown to have in vivo anti-
tumor effects by promoting cell cycle arrest and apoptosis
in transformed cells [135, 143, 144].
Moreover, engagement of RIG-I and MDA5 is known to
induce pro-apoptotic signaling in addition to transcription
of IFNs themselves [145, 146]. Similarly, apoptosis
induction has been described downstream of TLR3 and 4
[142, 144, 147]. Interferons positively regulate the expres-
sion of these receptors, thereby rendering cells further
susceptible to death. Altogether, certain effects of type I
IFNs might cumulate, thereby sensitizing cells to apoptosis.
Autoimmunity and pro-inflammatory effects
Although beneficial for host immune responses, type I
IFNs are also involved in the pathogenesis of certain dis-
eases. Type I IFNs marry immuno-stimulatory to pro-
apoptotic effects, which together make these cytokines
particularly suited to favor autoimmune manifestations.
Indeed, elevated production of inflammatory cytokines,
such as type I IFNs, activates DCs. Moreover, these cyto-
kines can promote tissue damage, therefore inducing the
release of apoptotic material, which can be further
phagocytosed and presented by activated antigen-present-
ing cells. These effects might be detrimental in individuals
prone to develop autoimmunity due to an increased risk of
activating autoreactive lymphocytes [148–150].
First indications that type I IFNs might be key players in
autoimmunity came from the observation that the admin-
istration of these cytokines as antiviral or anti-proliferative
therapy was associated with autoimmune manifestations
[149, 151]. However, most of the time, symptoms resolved
when the therapy was stopped, indicating that type I IFNs
may initiate the development of autoimmunity but other
factors are required to sustain the disease [97, 149].
Administration of IFN-a more than IFN-b was found to be
associated with the onset of such autoimmune manifesta-
tions, which supports the hypothesis that there are
differences in the action of type I IFN subtypes. Accord-
ingly, reports suggest a more pronounced pathologic and
driving role for systemic IFN-a in the development of
autoimmunity [97, 98].
Indeed, an ‘IFN signature’, characterized by elevated
IFN-a levels and expression of type I IFN-regulated genes,
is found in systemic lupus erythematosus (SLE) patients
and correlates with immune cell activation and clinical
disease manifestations (Table 2). Systemic lupus erythe-
matosus is a systemic autoimmune disorder that can affect
any part of the body. This disease is characterized by the
deposition of immune complexes leading to inflammation,
and one of the pathologic features and diagnostic criteria of
SLE is the presence of anti-nuclear antibodies.
Dying cells release cellular material, which is then rec-
ognized by PRRs, inducing an inflammatory response.
Released intracellular components are also antigenic
determinants for B cells, triggering antibody production
against self-DNA and -RNA. This leads to the formation of
immune complexes, which may even promote delivery of
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nucleic acids to immune cells, therefore enhancing IFN
production [152–154]. The overproduction of type I IFNs
results in a chronic activation of DCs, which further sustains
the response of autoreactive lymphocytes in predisposed
individuals, thus promoting the vicious circle [133].
The specific nature of the autoantigens in SLE may be
instrumental in dictating the deleterious role of IFN-a in
this disease. Cytoplasmic delivery of nucleic acids leads to
activation of innate immune sensors, including the AIM2
inflammasome, whose components are further induced by
type I IFNs, as discussed below. Under these circum-
stances, AIM2 inflammasome engagement may lead to
enhanced IL-18 production, which has been involved in
disease progression [155]. Interestingly, AIM2 belongs to
the Ifi200 gene family, which in the mouse clusters within
the Nba2 lupus susceptibility locus [156].
Although the strongest genetic factor associated to SLE
is the human leukocyte antigen (HLA) region on chromo-
some 6 [157], many polymorphisms map to genes of the
type I IFN pathway, further suggesting that these cytokines
might play a detrimental role in this disease. In fact, IRF5
and TYK2 polymorphisms have been linked to increased
risk of SLE [97, 158]. Moreover, a pathological role of type
I IFNs is supported by studies from mouse lupus models
showing that genetic ablation of Ifnar1 leads to less severe
autoimmune manifestations [159, 160]. Against this com-
monly accepted view, few recent reports claim a protective
role for type I IFNs in SLE, a surprising finding that
requires more in-depth analysis [161, 162].
An IFN signature could also be detected in other auto-
immune diseases like Sjo¨gren’s syndrome and in a subgroup
of rheumatoid arthritis patients [97, 163, 164]. Rheumatoid
arthritis is mainly characterized by inflammation of the
joints and autoantibody production, while Sjo¨gren’s
syndrome is a lymphoproliferative disease characterized by
xerostomia (dry mouth) and xerophtalmia (dry eyes).
Whereas, in SLE, a pathologic role for type I IFNs is
established, a causative role for these cytokines in rheuma-
toid arthritis and Sjo¨gren’s syndrome has not been
determined, leaving open the possibility that they are pro-
duced in the inflammatory context as anti-inflammatory
mediators [97, 163, 164]. In the case of Sjo¨gren’s syndrome,
this is supported by the fact that elevated levels of IL-1Ra
have been detected in the cerebrospinal fluid of patients, and
that oromucosal administration of IFN-a significantly
increased unstimulated whole saliva flow, thus having a
modest therapeutic effect [165, 166]. In the case of rheu-
matoid arthritis, a possible anti-inflammatory function of
type I IFN is suggested by the protective role of IFN-b in
animal models of collagen-induced as well as antigen-
induced arthritis [167–169]. Moreover, an open phase I
study, in which 12 patients with rheumatoid arthritis were
treated with IFN-b subcutaneously, demonstrated modest
clinical improvement [170]. However, a double-blinded
placebo-controlled trial of IFN-b-1a (recombinant IFN-b
produced in mammalian cells) in rheumatoid arthritis
patients did not show any significant difference in radio-
logical scores or clinical outcomes [171].
Anti-inflammatory effects of type I IFNs
Experimental evidence
Anti-inflammatory effects in sterile and infectious models
Multiple lines of evidence indicate that type I IFNs also
exert anti-inflammatory functions. It has been known for a
Table 2 Current understanding of the role of IL-1 and type I IFNs in selected inflammatory disorders
Disease Main trigger, involved genes Role for IL-1 IL-1-blocking
agents in
patients
Refs Rec. IFN
therapy
Refs
Monogenic
auto-inflammatory
diseases
FMF MEFV mutations a a [288–295] a [296]
Polygenic
auto-inflammatory
diseases
IBD NOD2, ATG16L1, IRGM,
IL-12Rb, IL-23R, STAT3,
IL-10Rb mutations
a n.d. [304], [306] a [310–312]
Mixed pattern
diseases
Behc¸et HLA-B51 association, IL-
12Rb, IL-23R, IL-10
variants
b a [295], [318] a [319]
Atopic disorders Allergy Allergens, complex a n.d. [322–332] a [336]
Autoimmune
diseases
SLE IRF5, STAT4, TLR7, TYK2,
IRAK1, IKK-e variants
b b [344–347] n.d. (pathological role)
MS Specific HLA alleles, complex a n.d. [20], [241–244] a [228, 229]
refs references, rec recombinant, n.d. not determined, a established, b potential role
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long time that type I IFN administration can be beneficial
in a number of sterile inflammatory models, such as skin
reactivity test, collagen-induced arthritis, or allotransplant
rejection [59, 172–174]. Interferon-b also leads to a
reduced reaction upon neutrophil-induced blood–brain
barrier rupture [175] and in experimental autoimmune
encephalomyelitis (EAE) [176], both models mimicking
inflammatory aspects of the central nervous system found
in MS. Interestingly, IFN has a direct stabilizing effect on
cerebral endothelial cells lining the blood–brain barrier in
in vitro and EAE models [176, 177]. These data suggest
that the decreased passage of autoreactive lymphocytes
through the endothelium might be one of the modes of
action of IFN-b in MS, as discussed later.
In addition, while in virtually all viral and most bacterial
infections type I IFNs are advantageous or even required
for resistance [178], recent evidence shows that in some
instances IFN induction can also have unfavorable out-
comes. On the one hand, these effects can be due to a
disproportionate production of type I IFN leading to an
excessive inflammation, such as for cerebral malaria [179].
On the other hand, anti-inflammatory effects can dampen
the immune response, which results in an exacerbated
infection. This is the case for Francisella tularensis [180]
and Listeria monocytogenes, as well as for the protozoan
Leishmania amazonensis [181–183]. These infections were
found to be less detrimental and also have reduced infec-
tious burden in Ifnar-/- mice, showing that IFNs can
indirectly favor microbial outgrowth.
Mycobacterium tuberculosis infection was also shown to
be less severe in Ifnar-/- mice, with similar or reduced
bacterial burdens as compared to control mice [184, 185].
Of note, patients infected with M. tuberculosis show an
IFN signature, which might therefore have a pathogenic
role during infection [186].
Finally, another line of evidence for the anti-inflamma-
tory effects of IFNs comes from superinfections. In most
cases, influenza-related deaths do not derive from the viral
infection per se but from bacterial superinfections. A recent
study revealed that secondary Streptococcus pneumoniae
infections are worsened by the anti-inflammatory effects of
influenza-induced type I IFNs [187]. Similarly, fungal
infections can be exacerbated by type I IFNs. Mice pre-
treated with type I IFN-inducing RNAs are more suscep-
tible to candidiasis than untreated controls, an effect
abolished in Ifnar-/- mice [188–190].
Type I IFN-dependent inhibition of IL-1 production
The first molecular mechanisms for these anti-inflamma-
tory phenomena was proposed in 1990 when Schindler
et al. showed that IFN-a has the ability to reduce IL-1
production [191, 192]. As discussed above, production of
active IL-1 has to fulfill several conditions, and its activity
is further regulated by the existence of a natural antagonist
and a decoy receptor, IL-1RII. Additionally, IL-1 synthesis
and inflammasome function are targeted by several nega-
tive regulatory mechanisms (reviewed in [46, 193]).
Interestingly, type I IFNs have the ability to suppress pro-
IL-1 levels and decrease the activity of NLRP1 and NLRP3
inflammasomes [188]. The effects of type I IFNs on IL-1
production have been known for decades, and several
studies contributed to the understanding of the underlying
mechanisms, as schematically illustrated in Fig. 3 [59, 188,
192, 194–196]. Of note, both IFN-a and -b are able to exert
this anti-inflammatory effect.
In addition to reducing the expression of a number of
inflammatory genes, including TNF and the IL-12/IL-23
subunit p40, type I IFNs reduce the levels of IL-1a and pro-
IL-1b [120, 188, 192, 194–198]. Suppression of IL-1a and
-b has been reported to occur both at the transcriptional as
well as at the translational level [199, 200].
It recently became clear that this mechanism is relevant
to infectious diseases. In fact, IL-1 is instrumental for
resistance to both M. tuberculosis infection and systemic
candidiasis, suggesting that IFN-dependent suppression of
IL-1 production might be one mechanism explaining the
detrimental effects of type I IFN in these models [184, 199,
201–204]. Interestingly, in the context of M. tuberculosis
infection, adaptive immune cell-derived type II IFN has
also been found to suppress IL-1 production [184].
Although the anti-inflammatory contribution by IFN-c is
controversial, emerging evidence highlights an inhibitory
role of type II IFN on IL-1 levels, which seems to be
dependent on the context and on the target cell type [184,
188, 192, 205].
Additionally, type I IFNs induce the expression of anti-
inflammatory genes, such as IL-1Ra and IL-10 (Fig. 3)
[194, 195, 206]. In fact, type I IFNs synergize with LPS to
induce IL-10 [188, 207–210]. In the human system, this
effect is thought to occur through the transcription factor
STAT3 or the PI3K pathway [211, 212]. However, the use
of macrophages derived from different knockout mice
indicated that IL-10 induction downstream of type I IFNs
depends on STAT1, most likely as part of the canonical
signaling complex comprising STAT2 and IRF9 [188].
Interleukin-10 is one of the major anti-inflammatory
cytokines, which increases IL-1Ra transcription and neg-
atively regulates IL-1a and pro-IL-1b levels (Fig. 3) [188,
208, 209, 213, 214]. We found that the inhibitory effects of
type I IFNs on pro-IL-1 levels in macrophages are in part
achieved through autocrine IL-10 signaling [188]. Inter-
leukin-10-dependent regulation of pro-IL-1 has been
shown to mainly occur at the transcriptional level [208,
213, 214]. Furthermore, as IL-10 induces IL-1Ra [214], the
question arises as to which extent the IFN-dependent
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IL-1Ra induction could also be mediated by autocrine IL-
10 signaling.
Emphasizing their highly complex role in the balance
between inflammatory and anti-inflammatory effects, it has
been shown that type I IFNs have the ability to both pos-
itively and negatively regulate inflammasome activity. In
fact, IFNs play an important pro-inflammatory role, for
instance in sensitizing cells to certain bacterial inflamma-
some activators such as F. tularensis, and in the
maintenance of AIM2 expression [215, 216]. Interferons
are thus favoring the activity of the DNA-sensing AIM2
inflammasome, which is important upon infection by
cytosolic bacteria and DNA viruses [215, 216]. In addition,
caspase-1 itself, although being constitutively expressed, is
a transcriptional target of type I IFN [155, 217]. Interest-
ingly, IFNs not only seem to alter the activity of different
inflammasomes but also the abundance of their substrates;
while IL-1a and pro-IL-1b levels are decreased, the amount
of pro-IL-18 is augmented [155, 198].
In contrast, exogenous type I IFNs are clearly anti-
inflammatory, suppressing the activity of the NLRP3 in-
flammasome, which is a sensor for a broad range of stimuli
[188]. This effect is transient and requires higher doses of
IFNs than the one on pro-IL-1, at least in macrophages
[188]. Although experimental data indicate that this
inhibitory effect requires the transcription factor STAT1,
the underlying mechanisms currently remain unclear.
Interestingly, it was recently suggested that IFI16, which is
strongly induced by type I IFN treatment, might be
involved in this process [218]. In fact, knockdown of this
DNA-binding protein in THP1 cells, a monocytic myeloid
cell line, clearly increased the basal caspase-1 processing,
indicating an augmented inflammasome activity.
Altogether, the complex effects of type I IFNs on
inflammasome activity suggest that these cytokines favor
the activity of the AIM2 inflammasome, possibly in concert
with the production of IL-18, while impairing the activity
of the NLRP3 inflammasome along with the production of
IL-1. In the case of a viral infection, this might hinder
development of a Th17 and favor a tailored Th1 type of
response.
Established type I IFN-based clinical treatments
Therapeutic use of type I IFNs in viral and neoplastic
diseases
Type I interferons are classical antiviral effector molecules.
It is therefore not surprising that they have been studied as
potential therapies for a number of viral diseases. Inter-
feron-a is currently used in combination with other
medications as a standard treatment for hepatitis B and C
infections and may also reduce the occurrence of associ-
ated hepatocellular carcinoma [219–221]. Moreover, IFN-a
was shown to be effective against human herpesvirus
8-driven Kaposi sarcoma and genital warts caused by
papilloma viruses [222, 223]. Although its antiviral prop-
erties could per se explain the beneficial effects of IFN-a in
these virus-associated neoplasms, the synergy with its
ability to promote apoptosis, modulate immune functions,
Fig. 3 Type I IFNs inhibit IL-1
production. Type I IFN
signaling suppresses caspase-1-
dependent IL-1b maturation by
a STAT1-dependent
mechanism, which might
involve de novo transcription of
a target protein. In addition,
type I IFNs induce the
expression of IL-1Ra, the
natural IL-1R antagonist, and
the anti-inflammatory cytokine
IL-10. In murine macrophages,
enhancement of IL-10
production by type I IFNs also
requires the transcription factor
STAT1. Interleukin-10, in turn,
contributes to the induction of
IL-1Ra and to the decrease of
pro-IL-1 levels in a STAT3-
dependent manner
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and alter tumor microenvironment is likely to contribute to
this outcome [224]. On the one hand, IFN-dependent
reduction of viral load could alone decrease inflammation
by removing viral-derived PAMPs. On the other hand,
IFN-a has also been successfully used in the therapy of
malignancies, which are not considered to be associated
with viral infections, where its effects are not mediated by
the control of viral load. In particular, beneficial effects
were observed in hairy cell leukemia, chronic myeloid
leukemia, and melanoma [224–226].
Therapeutic use of type I IFNs in multiple sclerosis
Furthermore, for almost 20 years, IFN has been known to
reduce inflammation in MS (Table 2) [97]. Multiple scle-
rosis is an inflammatory autoimmune disorder of the brain
and the spinal cord and represents the second most com-
mon cause of neurological disability in young adults,
exceeded only by trauma [227]. Affected patients suffer
from relapses of neurological deficits that affect the white
matter of the brain and the spinal cord. These are caused by
autoreactive T cells that attack the myelin sheath, resulting
in defective neural transmission. At least in the early stage
of the disease, there is a more or less full recovery after
each relapse, a form named relapsing-remitting phase (RR-
MS). However, more than 80 % of patients with RR-MS,
after 10–15 years, see their neurological symptoms pro-
gress unremittingly, without any relapses. At this stage, one
speaks of secondary-progressive MS.
Interferon-b is used for the treatment of patients suf-
fering from a first episode suggestive of MS (clinically
isolated syndrome) and of patients with RR-MS. Pivotal
studies have shown a reduction in the frequency of relapses
by about 30 % over 2–3 years of treatment with IFN
(reviewed in [228]). In a large clinical trial, administration
of IFN-b was shown to marginally, but still significantly,
decrease the rate of accumulation of disability over 3 years
[229]. However, once the secondary progressive stage of
the disease is reached, these therapies lose their efficacy,
suggesting that IFN-b acts more on the inflammatory than
on the neurodegenerative phase of the disease.
Interferon-a has also been studied as a treatment
modality in MS. In one small study, IFN-a-2a (recombinant
IFN-a produced in Escherichia coli) has been found to be
effective in reducing exacerbations in MS patients as
compared to placebo [230]. Additional encouraging find-
ings have been reported in a trial of natural human
leukocyte IFN-a in MS patients [231]. However, several
reports have appeared on the potential of recombinant
IFN-a to exacerbate the course of MS, including in patients
with the progressive form of the disease [232, 233]. An
MS-like syndrome has also been reported in a patient with
chronic myeloid leukemia treated with IFN-a [234]. Thus,
currently, IFN-a is not recommended as a treatment for MS.
Autoreactive lymphocytes are traditionally considered
to be the primary immuno-pathogenic mechanism in MS
for several reasons: (1) the adoptive transfer of myelin-
specific autoreactive T cells induces EAE in mice [235],
(2) perivascular cuffs of T lymphocytes are found in the
center of demyelinating lesions in the white matter in
human MS [236], (3) there is an oligo-clonal expansion of
CD8? T cells in brain lesions of MS patients, suggesting
that these cells recognize an antigen in the central nervous
system [237], (4) the central role of T cells is supported by
genetic association of specific HLA alleles with MS [228],
and (5) B cell infiltration and immunoglobulins are detec-
ted in MS lesions [238].
However, despite a sustained effort in research, the
precise etiology(ies) of MS remain(s) to be established.
Comprehensive studies of the adaptive immunity have not
provided the whole picture of its immuno pathogenesis,
which points to the fact that MS is a complex and/or het-
erogeneous disease. In particular, no consistent auto-
antigen has been found. Therefore, an alternative model
proposes a pivotal role of a dysregulated innate immune
response that may impact the adaptive immune system by
the generation of autoreactive T and B cells [239, 240].
Interestingly, experimental evidence highlights a role for
inflammasome components and IL-1 in EAE progression,
as mice deficient for caspase-1, ASC, NLRP3, IL-1RI, or
IL-1a/b were significantly protected, while EAE in animals
deficient for IL-1Ra showed exacerbated progression [20,
241–244]. The fact that IFN-b targets the innate at least as
much as the adaptive arm of the immune system supports
the aforementioned hypothesis [245].
Proposed mechanisms of IFN-b efficacy in multiple
sclerosis
Originally, the efficacy of IFN-b in MS was attributed to its
ability to decrease inflammatory cytokine production while
increasing the expression of anti-inflammatory mediators
[191, 192, 194–198, 206]. Of note, monocytes derived
from IFN-b-treated MS patients produced significantly
lower amounts of IL-1b upon ex vivo challenge with
inflammasome activators, as compared to monocytes from
healthy donors [188]. This suggests that the efficacy of
IFN-b treatment might in part be caused by this anti-
inflammatory mechanism. Moreover, the pro-apoptotic
effects on activated autoreactive T cells, which cause
damage in the central nervous system, were believed
to contribute to IFN-b effectiveness in MS treatment
[192, 194, 195, 246]. Later studies added IFN-b-activated
STAT3 signaling as a main player in the anti-inflammatory
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effects. It does so by promoting the expression of Src
homology phosphatase-1, an inhibitor of cytokine signal-
ing, and blocking the activation of inflammatory mediators,
such as NF-jB and STAT6 [247–249].
Moreover, IFN-b has been proposed to negatively
influence trafficking of immune cells to the inflamed cen-
tral nervous system. One mechanism involves the
inhibition of lymphocyte egress from lymph nodes.
Sphingosine 1-phosphate receptor-1 is required for this
process and is negatively regulated by type I IFNs, thus
reducing the number of circulating effector T cells [250].
In addition, IFN-b also decreases the ability of T cells to
migrate to the central nervous system by stabilizing the
blood–brain barrier, downregulating integrin expression on
T cells, and affecting the function of matrix metallopro-
teases, which are important for cell migration and adhesion
[177, 251–254].
More recently, the Th17-opposing effects of type I IFNs
have gained attention. In fact, studies in MS patients and
EAE have shown that Th17 cells are involved in these
autoimmune manifestations [255]. Interferons could
therefore also exert their beneficial effects in the treatment
of MS by hindering the development of Th17, a possible
mechanism being the reduction of IL-1 levels [120].
Only about two-thirds of MS patients respond well to
treatment with IFN-b in terms of decreased relapse rates
and fewer new brain and spinal cord lesions [256].
Identifying so-called ‘non-responders’ prior to the initia-
tion of therapy is of obvious clinical interest, and multiple
studies have looked at ways to predict a patient’s
‘responder’ status. One study of MS patients treated with
IFN-b demonstrated that non-responder and responder
phenotypes differ in their ex vivo gene expression profiles
as assessed by magnetic resonance imaging scanning and
clinical disease activity. In particular, IL-8, an important
chemotactic mediator recruiting neutrophils to sites of
inflammation, was found to be significantly downregu-
lated ex vivo and in vitro in IFN-b treated responders but
not in non-responders. In addition, expression of a num-
ber of genes involved in either regulation of proliferation
or apoptosis were modified in responders towards an anti-
proliferative pro-apoptotic state. In non-responders, how-
ever, this shift was either absent or observed to a
significantly lesser degree [257]. Another study has sug-
gested that high concentration of IL-17F, another member
of the IL-17 family, in the serum of patients with RR-MS
is associated with non-responsiveness to IFN-b therapy
[258]. Furthermore, it has been proposed that, in certain
subpopulations of MS patients, IFN-b treatment could
worsen the disease [259]. This differential response to
therapy highlights the fact that MS is a heterogeneous
disease and that other factors, such as genetic ones, are
important players in the susceptibility to the treatment
[238].
Adverse effects and drawbacks of IFN treatment
Just as any treatment, type I IFNs can have side effects. Up
to 75 % of patients treated with IFN-b experience flu-like
symptoms such as fever, headache, muscle pain, fatigue,
and chills [260]. The most common observed laboratory
abnormalities are elevation of liver enzymes and leuko-
penia. These changes are seldom serious, generally
reversible, and rarely warrant the discontinuation of the
treatment [261–267]. However, reports on fulminant liver
failure as well as on unmasking of pre-existing autoim-
mune hepatitis or psoriasis do exist [268–270]. Hence, the
regular monitoring of liver enzymes is recommended.
Reports of depression associated with IFN therapy (both
IFN-a and -b) are well known. However, controversy still
exists on whether it is caused by IFN. For instance,
depression is quite common in MS patients irrespective of
the treatment they are undergoing. A recent review has
described 11 cases of severe depression with suicide
attempts among patients treated with IFN-b who had no
prior psychiatric history [271]. Yet, other studies found no
evidence to support the claim that IFN-b can cause or
exacerbate depression [272].
Occasionally, IFN therapy can lead to the development of
autoimmune manifestations in the form of SLE, arthritis, and
diabetes [97, 149, 151]. However, most of these complica-
tions resolve upon discontinuation of treatment. Rarely, a
syndrome resembling thrombotic thrombocytopenic pur-
pura with fever, thrombocytopenia, and renal failure has
been reported in MS patients treated with IFN-b-1a [260].
In addition, chronic therapy with IFN-b can be associ-
ated with development of antibodies neutralizing IFN. In
initial trials of different IFN-b preparations in MS patients,
frequencies of neutralizing antibodies varied from 7 to
42 % [262, 273–275]. However, these percentages often
depend on the method used to detect antibodies. It has
previously been reported that up to 80 % of serum samples
from patients treated with IFN-b for more than 1 year
contained measurable amounts of neutralizing antibodies
when assessed with an optimized assay [276]. It has been
demonstrated that the presence of antibodies against IFN-b
in the sera of MS patients may reduce the clinical efficacy
of this medication as manifested by increased relapse rates
[277]. Switching the therapy is recommended for neu-
tralizing antibody-positive patients that have experienced
worsening of their disease course. However, provided that
the patient is without exacerbations on IFN-b treatment, it
is generally not necessary to check the neutralizing anti-
body status.
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Potential clinical treatments based on type I IFN
Excessive inflammatory reactions can originate from a
disproportioned inflammatory response or from a mal-
functioning control mechanism, and can have an acquired
or a genetic origin. In fact, we define a wide range of
pathological manifestations with the term ‘inflammatory
disorders’, all sharing inflammatory features, but resulting
from profoundly different causes [278]. Thus, the spectrum
of inflammatory diseases spans from pure ‘auto-inflam-
matory’ ones, which are disorders without any involvement
of the adaptive immune system, to classical autoimmune
pathologies.
The origin of several auto-inflammatory diseases can
be solely attributed to deregulated IL-1 signaling [27].
This is the case for diseases such as cryopyrin-associated
periodic syndromes (CAPS; which include: familial cold
auto-inflammatory syndrome, Muckle–Wells syndrome,
and neonatal-onset multisystem inflammatory disease),
where activating mutations within the NLRP3 gene lead
to constitutive inflammasome activity [279]. The patho-
logical role of excessive inflammasome activity and IL-1
signaling in this disorder has been irrevocably proven by
the therapeutic efficacy of agents blocking IL-1 [280–
285]. Given the clear molecular basis and the straight-
forward therapeutic approaches, we do not discuss such
auto-inflammatory disorders in this review. Instead, we
focus on diseases with more complex origin, with IL-1
being involved but not being the unique cause of the
pathogenesis, and where novel therapeutic approaches are
needed.
In the following paragraphs, we therefore discuss rep-
resentative disorders with regard to the role of type I IFNs,
inflammasomes and IL-1 (as summarized in Table 2).
Familial Mediterranean fever
Familial Mediterranean fever (FMF) is manifested by fever
episodes along with local inflammatory reactions such as
peritonitis, arthritis, skin rashes, and in some cases amy-
loidosis. Patients bear mutations in the Mediterranean fever
(MEFV) gene, also known as pyrin, and such variants are
encountered with higher frequency in populations from the
Mediterranean basin and the Middle East [286, 287].
Although to date an excessive IL-1 production in FMF
patients has not been consistently measured and the nature
of mutations affecting pyrin is not firmly established, it is
clear that these patients respond to IL-1 blocking biologics
[27, 288–295]. Interestingly, IFN-a treatment was also
found to be promising in the management of colchicine-
resistant FMF patients [296]. This suggests that the ability
of type I IFN to interfere with IL-1 production may be
relevant in this therapeutic context.
Inflammatory bowel disease
Inflammatory bowel disease (IBD) is a heterogeneous
group of inflammatory disorders of the intestinal tract,
including Crohn’s disease and ulcerative colitis. Crohn’s
disease is characterized by discontinuous and transmural
inflammatory manifestations. In 2001, two independent
studies showed a clear association of this disease with
variants of NOD2, a member of the NLR family [297, 298].
Later studies identified a number of other genes as hotspots
for mutations, including IL-23R, STAT3, immunity-related
GTPase family M (IRGM), and autophagy-related 16-like 1
(ATG16L1) [299–303]. Nucleotide-binding oligomerization
domain-containing protein 2 (NOD2), immunity-related
GTPase family M protein (IRGM) and autophagy-related
protein 16-1 (ATG16L1) control autophagy, which interest-
ingly seems to be an important negative regulator of
inflammasome activity as shown in IBD models [304–306].
Furthermore, Atg16L1-deficient mice show increased intes-
tinal inflammation and IL-1 secretion [304, 306].
Whereas in Crohn’s disease the inflammation can be
found anywhere in the digestive tract, ulcerative colitis is
characterized by an inflamed large intestine and rectum,
only in some cases spreading to the small intestine. A
direct cause of ulcerative colitis is so far not known, but
environmental factors, immune dysfunction, and a pre-
sumed genetic predisposition were proposed to contribute
to disease pathology. Interestingly, IL-23R, and STAT3 are
common risk loci associated with both ulcerative colitis
and Crohn’s disease. Interleukin-23R also signals through
the transcription factor STAT3, clearly identifying the
IL-23 pathway as a key player in the development of IBD.
zInterleukin-23 plays a very important role in Th17 responses
and has been associated with autoimmune disorders, thus
highlighting the contribution of the adaptive immune branch
to this disease. However, STAT3 is also implicated in sig-
naling downstream of the anti-inflammatory IL-10, and
several reports strongly link IBD to mutations affecting IL-10
signaling [301, 307, 308].
Besides the classical anti-inflammatory treatments, anti-
TNF biologics have been successfully used in the man-
agement of IBD, and shown to prevent deleterious tissue
damage [309]. Interestingly, type I IFNs have been repor-
ted to be beneficial in the treatment of ulcerative colitis
[310, 311]. A proposed mechanism is the shift towards a
Th1 polarization mediated by type I IFNs in a Th2-pre-
dominant disease like ulcerative colitis [312].
Behc¸et disease
Behc¸et disease is a chronic multifocal inflammatory dis-
order with mucocutaneous, ocular, vascular, skeletal, and
central nervous system manifestations. Strong associations
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with specific HLA alleles have been identified, and also,
albeit less pronounced, with IL-10 and IL-23 signaling
pathways [313, 314]. Despite the strong link to certain
HLAs and the important presence of CD4? T cells in
inflamed areas, direct contribution by these HLAs to a
potential autoreactive response has not been determined
[315].
For patients refractory to traditional immunosuppressive
and anti-inflammatory therapies, encouraging results have
been observed using TNF and IL-1 antagonist, and, inter-
estingly, IFN-a [295, 316–319]. Therefore, both IL-1
inhibition and type I IFN treatment are helpful for the
management of Behc¸et disease, suggesting that part of type
I IFN efficacy in this context might be due to its suppres-
sion of IL-1 production.
Atopic disorders
Allergies are frequent inflammatory disorders originating
from both genetic and environmental factors. One of the
hypotheses to explain the widespread prevalence of these
disorders in developed countries relies on the hygienic
habits adopted by our society. Under these circumstances,
the immune system would compensate its inactivity
towards pathogens by attacking otherwise inert antigenic
determinants, such as pollen-derived ones [320]. None-
theless, several allergens are endowed with enzymatic
functions, thus having immuno-stimulatory properties
[321].
Atopic responses can be found in different tissues,
including skin, airway mucosa, and conjunctiva, and are
associated with Th2 polarization. In fact, Th2 inflammatory
cytokines promote all the typical features of allergic
reactions, such as excessive production of immunoglobulin
E, mast cell activation, and eosinophilia. Antibody-allergen
complexes are crucial to crosslink Fc-receptors on mast
cells, thus leading to the release of pre-stored granules
containing, among other substances, histamines.
Multiple links between IL-1 and allergy have been
reported. Firstly, IL-1 supports the production of several
chemokines and cytokines, which are involved in atopic
reactions, and can synergize with other Th2 cytokines to
activate mast cells [321–323]. Secondly, IL-1 is detected
upon allergen challenge, and mast cells are capable of
producing bioactive IL-1 [324, 325]. Besides their role in
Th17 differentiation, inflammasome activators have also
been suggested to promote Th2-biased polarization,
although a specific role for inflammasome or IL-1 in this
process has not been unambiguously shown [326–335].
Interestingly, IFN treatment alleviates asthma; this could
rely on a type I IFN-induced Th2 to Th1 shift, and the
suppression of IL-1 production could also contribute to this
effect [336].
Cancer
Our understanding of the interplay between inflammation
and cancer has profoundly changed. A decade ago, an
increased inflammation within tumor environment was
perceived as a potentially beneficial feature, able to attract
and activate immune cells. However, there is now
increasing evidence that inflammation can also exert det-
rimental effects, favoring tumor growth, angiogenic switch,
and metastasis [337]. This makes IL-1 a double-edged
sword, which in some settings favors tumor regression, but
in others helps its progression (for a more detailed dis-
cussion, see [46, 338]).
Interferon-a therapy has proven efficacious for treating
several virus-associated tumors, myeloproliferative disor-
ders, hairy cell leukemia, and melanomas, particularly
ulcerated ones, as discussed in the section ‘‘Therapeutic use
of type I IFNs in viral and neoplastic diseases’’ [224, 226].
Besides its pro-apoptotic features, the anti-angiogeneic
properties of type I IFNs could play an important role in the
case of solid tumors [339].
Interestingly, the properties of IL-1 in promoting
myeloproliferation through positive regulation of granulocyte–
macrophage colony-stimulating factor, and in induction of
vascular endothelial growth factor have been consistently
reported [14, 340–343]. This suggests that the action of
IFN-a on IL-1 production might also contribute to the
suppressive effects of IFNs on myeloproliferative disorders
and angiogenesis.
Concluding remarks
As discussed, IFN therapies are effective in the management
of viral, malignant, and autoimmune disorders. It goes
without saying that in diseases of viral origin, such as hep-
atitis, the contribution by IFNs in controlling viral load is
crucial. Nonetheless, suppression of certain inflammatory
components can be beneficial in all these diseases. Indeed,
the anti-inflammatory effects of IFN-a and -b have been
recognized in sterile and infectious experimental models as
well as in the clinic. The strongest evidence for the surprising
anti-inflammatory role of type I IFNs comes from the
treatment of MS, where pro-apoptotic, immunomodulatory,
and anti-inflammatory effects of IFN-b converge to a ben-
eficial outcome. Whereas IFN-b is virtually uniquely used in
the treatment of MS, the therapeutic administration of IFN-a
ranges from viral infections to tumors. However, a com-
prehensive analysis of the possible molecular mechanisms
behind this divergent use of type I IFNs is so far missing.
One important feature of inflammatory pathologies
resides in the nature of the inflammation; at one extreme,
we can place disorders of pure innate origin. In many of
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these pathologies, IL-1 plays an important role, as wit-
nessed by the efficacy of treatments targeting this cytokine.
It is, however, important to mention that in some auto-
inflammatory syndromes, a possible contribution of auto-
reactive T and B cells has so far been disregarded. At the
opposite end of the inflammatory disease spectrum are rare
monogenic autoimmune disorders affecting the adaptive
immune system, such as autoimmune polyendocrinopathy
syndrome. Inbetween these extremes, there are disorders
that involve both innate and adaptive immune cells.
Recently, the effectiveness of anti-IL-1 treatment is
becoming appreciated in disorders with such complex eti-
ology as Behc¸et or Type 2 diabetes. These observations
encourage extending the use of anti-IL-1 agents, which are
specific, safe, and well tolerated [283–285].
In addition, experimental results point to a crucial con-
tribution of IL-1 in a number of inflammatory syndromes,
including those currently treated with IFNs. Given the
strong ability of type I IFNs to dampen IL-1 production, it
is conceivable that IFNs might be considered as anti-
inflammatory agents in a broader range of complex
inflammatory diseases where a role for IL-1 has been
reported. The combined administration of type I IFNs
together with IL-1 neutralizing agents might enforce the
anti-inflammatory properties of IFNs, thus increasing
treatment efficacy. Possibly, this may also allow the
reduction of the administered dose of IFNs, thereby
improving tolerability.
However, the effects of IFNs are pleiotropic and their
use warrants caution because of their potential side effects.
Instead of broadening the use of type I IFNs in the clinic,
we might take advantage of the growing knowledge on the
multiple anti-inflammatory effects of type I IFNs and use
agents that specifically target selected pathways down-
stream of these cytokines. Such approaches might represent
valuable alternatives to the use of IFNs. We have high-
lighted how therapies targeting IL-1 signaling can mimic
one of the important anti-inflammatory effects of IFNs.
Another example are sphingosine analogs, which have
been recently approved for MS treatment and that act by
sequestering lymphocytes within lymph nodes. Finally, it is
possible that IL-1-blocking agents could be well comple-
mented by or even synergize with treatments that target
other specific aspects of inflammatory diseases and could
therefore provide an even more efficient therapy.
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